Paquinimod
Paquinimod has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Jan 26, 2026: “Calprotectin Is a Circulating Biomarker and Potential Therapeutic Target for Sarcopenia in Chronic Obstructive Pulmonary Disease”.
See all 1 papers on paquinimod
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Fundamental Research Funds for the Central Universities and 2 more
- Animals1
What did studies of paquinimod find?
2Studies of paquinimod measured 2 outcomes: ubiquitin–proteasome system and grip strength.
Ubiquitin–proteasome system
downin mice1
1 study
Ubiquitin–proteasome system
downin mice1
Paquinimod inhibits ubiquitin–proteasome system in cigarette smoke-exposed mice.
“Paquinimod inhibited ubiquitin-proteasome system activity, reduced protein degradation marker levels, attenuated oxidative stress and increased antioxidant enzyme levels in CS-exposed mice.”
Animalsin cigarette smoke-exposed miceskeletal muscle
Journal of cachexia, sarcopenia and muscle
Grip strength
upin mice1
1 study
Grip strength
upin mice1
Paquinimod improves grip strength in cigarette smoke-exposed mice (214.9 ± 31.38 g vs. 333.1 ± 34.93 g, p < 0.01).
“Paquinimod also reduced CS-induced muscle weakness, as indicated by increased grip strength (214.9 ± 31.38 g vs. 333.1 ± 34.93 g; p < 0.01).”
Animalsin cigarette smoke-exposed mice10 mg/kg/day
Journal of cachexia, sarcopenia and muscle